Literature DB >> 2014236

The molecular genetic basis of Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations in Israel.

P J Newman1, U Seligsohn, S Lyman, B S Coller.   

Abstract

Glanzmann thrombasthenia is an autosomal recessive bleeding disorder characterized by a decrease or absence of functional platelet glycoprotein (GP) IIb-IIIa (alpha IIb beta 3) integrin receptors. Although thrombasthenia is a rare disorder, its occurrence is increased in some regions of the world where intracommunity marriage and consanguinity are commonplace, resulting in increased expression of autosomal recessive traits. We have been studying two populations having an unusually high frequency of Glanzmann disease, Iraqi Jews and Arabs living in Israel, and were able to distinguish the populations on the basis of immunodetectable GPIIIa and platelet surface vitronectin receptor (alpha v beta 3) expression. In this article, we describe molecular genetic studies based on use of the PCR that have allowed us to characterize platelet mRNA sequences encoding GPIIb and GPIIIa from patients in these populations. In six of six Iraqi-Jewish families studied, cDNA sequence analysis identified an 11-base deletion within exon 12 of the GPIIIa gene. This mutation produces a frameshift leading to protein termination shortly before the transmembrane domain of GPIIIa. In contrast, a 13-base deletion encompassing the splice acceptor site of exon 4 of the GPIIb gene was found in three of five Arab kindreds studied. This deletion results in forced alternative splicing to a downstream AG acceptor, producing a 6-amino acid deletion in the GPIIb protein, including a single cysteine residue. These nucleotide sequence variations were exploited to design a rapid, PCR-based oligonucleotide dot-blot hybridization test for both pre- and postnatal diagnosis of Glanzmann disease. These studies demonstrate the heterogeneity of Glanzmann thrombasthenia in different populations, and its homogeneity within geographically restricted populations, and offer insight into the requirements for integrin surface expression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2014236      PMCID: PMC51405          DOI: 10.1073/pnas.88.8.3160

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Clinical and genetic aspects of Glanzmann's thrombasthenia in Israel: report of 22 cases.

Authors:  N Reichert; U Seligsohn; B Ramot
Journal:  Thromb Diath Haemorrh       Date:  1975-12-15

2.  Structure of the platelet membrane glycoprotein IIb. Homology to the alpha subunits of the vitronectin and fibronectin membrane receptors.

Authors:  M Poncz; R Eisman; R Heidenreich; S M Silver; G Vilaire; S Surrey; E Schwartz; J S Bennett
Journal:  J Biol Chem       Date:  1987-06-25       Impact factor: 5.157

3.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

4.  Prevention program of type I Glanzmann thrombasthenia in Israel: prenatal diagnosis.

Authors:  U Seligsohn; R S Mibashan; C H Rodeck; K H Nicolaides; D S Millar; B S Coller
Journal:  Curr Stud Hematol Blood Transfus       Date:  1988

5.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

6.  A Glanzmann's thrombasthenia cluster among Iraqi Jews in Israel.

Authors:  U Seligsohn; S Rososhansky
Journal:  Thromb Haemost       Date:  1984-12-29       Impact factor: 5.249

7.  Cloning of glycoprotein IIIa cDNA from human erythroleukemia cells and localization of the gene to chromosome 17.

Authors:  J P Rosa; P F Bray; O Gayet; G I Johnston; R G Cook; K W Jackson; M A Shuman; R P McEver
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

8.  Residual amounts of glycoproteins IIb and IIIa may be present in the platelets of most patients with Glanzmann's thrombasthenia.

Authors:  A T Nurden; D Didry; N Kieffer; R P McEver
Journal:  Blood       Date:  1985-04       Impact factor: 22.113

9.  Structure of platelet glycoprotein IIIa. A common subunit for two different membrane receptors.

Authors:  A B Zimrin; R Eisman; G Vilaire; E Schwartz; J S Bennett; M Poncz
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

10.  Biosynthesis and processing of platelet GPIIb-IIIa in human megakaryocytes.

Authors:  A Duperray; R Berthier; E Chagnon; J J Ryckewaert; M Ginsberg; E Plow; G Marguerie
Journal:  J Cell Biol       Date:  1987-06       Impact factor: 10.539

View more
  24 in total

Review 1.  Demystified...adhesion molecule deficiencies.

Authors:  D Inwald; E G Davies; N Klein
Journal:  Mol Pathol       Date:  2001-02

2.  Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factor.

Authors:  C Weber; T A Springer
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

3.  A new variant of Glanzmann's thrombasthenia (Strasbourg I). Platelets with functionally defective glycoprotein IIb-IIIa complexes and a glycoprotein IIIa 214Arg----214Trp mutation.

Authors:  F Lanza; A Stierlé; D Fournier; M Morales; G André; A T Nurden; J P Cazenave
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

Review 4.  Proteomic approaches to dissect platelet function: Half the story.

Authors:  Dmitri V Gnatenko; Peter L Perrotta; Wadie F Bahou
Journal:  Blood       Date:  2006-08-22       Impact factor: 22.113

Review 5.  The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend.

Authors:  Barry S Coller; Sanford J Shattil
Journal:  Blood       Date:  2008-10-15       Impact factor: 22.113

6.  Specificity of G alpha q and G alpha 11 gene expression in platelets and erythrocytes. Expressions of cellular differentiation and species differences.

Authors:  G J Johnson; L A Leis; P C Dunlop
Journal:  Biochem J       Date:  1996-09-15       Impact factor: 3.857

7.  Translating from the rivers of Babylon to the coronary bloodstream.

Authors:  Barry S Coller
Journal:  J Clin Invest       Date:  2012-11-01       Impact factor: 14.808

8.  Novel Pure αVβ3 Integrin Antagonists That Do Not Induce Receptor Extension, Prime the Receptor, or Enhance Angiogenesis at Low Concentrations.

Authors:  Jihong Li; Yoshiyuki Fukase; Yi Shang; Wei Zou; José M Muñoz-Félix; Lorena Buitrago; Johannes van Agthoven; Yixiao Zhang; Ryoma Hara; Yuta Tanaka; Rei Okamoto; Takeshi Yasui; Takashi Nakahata; Toshihiro Imaeda; Kazuyoshi Aso; Yuchen Zhou; Charles Locuson; Dragana Nesic; Mark Duggan; Junichi Takagi; Roger D Vaughan; Thomas Walz; Kairbaan Hodivala-Dilke; Steven L Teitelbaum; M Amin Arnaout; Marta Filizola; Michael A Foley; Barry S Coller
Journal:  ACS Pharmacol Transl Sci       Date:  2019-08-02

9.  A point mutation in KINDLIN3 ablates activation of three integrin subfamilies in humans.

Authors:  Nikolay L Malinin; Li Zhang; Jeongsuk Choi; Alieta Ciocea; Olga Razorenova; Yan-Qing Ma; Eugene A Podrez; Michael Tosi; Donald P Lennon; Arnold I Caplan; Susan B Shurin; Edward F Plow; Tatiana V Byzova
Journal:  Nat Med       Date:  2009-02-22       Impact factor: 53.440

10.  The platelet: life on the razor's edge between hemorrhage and thrombosis.

Authors:  Barry S Coller
Journal:  Transfusion       Date:  2014-08-05       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.